Screening for the Need of Palliative Care among Patients with Advanced, Incurable Cancer
- Conditions
- C00-C80: Malignant neoplasms (excluding malignant hematologic disorders)C00-C97Malignant neoplasms
- Registration Number
- DRKS00021686
- Lead Sponsor
- niversitätsklinikum Freiburg, Klinik für Palliativmedizin
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 216
Inclusion Criteria
Arm1 patients:
- Patients with metastatic or locally advanced, incurable cancer
- = 18 years
- Consent by patient or authorized representative
Arm2 team members:
- Team members of the PMD service of the University Hospital Erlangen, Freiburg and Cologne
- Consent
Arm3 patients:
- Oncological patients
- Sufficient knowledge of German and cognitive skills to complete a questionnaire
- Consent
Exclusion Criteria
Arm 1 patients:
- Malignant hematological diseases as the main oncological diagnosis
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method eed for specialist palliative care in incurable cancer patients: assessment after palliative medical history by at least one PMD team member and multi-professional case discussion in the PMD team <br><br>Sensitivity, specificity, and positive and negative predictive value for Patient Reported Outcome Measures (one-time completion of IPOS and distress thermometer questionnaires), disease-related and treatment-related information, and sociodemographic characteristics of patients
- Secondary Outcome Measures
Name Time Method - Examination of the interrater agreement of the assessment of palliative care needs between PMD and the treating oncologists<br>- Exploration of treatment objectives, treatment content, and treatment scope for PMD applications within the project<br><br>Due to the Covid-19 pandemic, general as well as disease- and care-related burdens of the patients must also be considered and recorded in the trial. In addition to the use of the data as moderator variables in the evaluation with regard to the primary project goals, a descriptive specification of the pandemic-related burdens of patients with advanced cancer will also be provided.